Form 4: Kura Oncology SVP Sells Shares for Tax Obligations

Kura Oncology's SVP of Finance and Accounting, Thomas James Doyle, sold 7,142 shares of common stock to cover tax obligations related to vested restricted stock units.

Summary

• Thomas James Doyle, SVP, Finance & Accounting of Kura Oncology, Inc. (KURA), reported the sale of 7,142 shares of common stock.
• All sales occurred on January 27, 2026, at a price of $8.4607 per share.
• The total value of the shares sold amounts to approximately $60,441.
• These transactions were 'sell-to-cover' sales, executed to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• The RSUs were received by Mr. Doyle on various dates, including January 2, 2024, February 16, 2023, January 26, 2022, January 2, 2025, and February 7, 2022.
• Following these transactions, Mr. Doyle directly beneficially owns 145,167 shares of common stock.
• Additionally, 500 shares are indirectly beneficially owned through his spouse's 401(k).

Sentiment

Score: 5

Explanation: The filing reports routine, non-discretionary 'sell-to-cover' transactions by an executive to satisfy tax obligations related to RSU vesting. This is a neutral event that does not reflect positively or negatively on the company's operational or financial performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Sell-to-cover transactions are a standard and routine practice for executives who receive equity compensation, such as Restricted Stock Units (RSUs). These sales are typically non-discretionary and are executed to cover tax liabilities incurred upon the vesting of equity awards, rather than indicating a change in investment sentiment or company fundamentals.

Comparison to Industry Standards

• The 'sell-to-cover' mechanism for tax obligations upon RSU vesting is a widely accepted and common practice across all industries for executive compensation. It aligns with standard corporate governance and tax compliance procedures for equity awards.
• This type of transaction is not indicative of a discretionary sale based on market outlook, unlike open market sales by insiders that are not pre-scheduled or tax-related.

Stakeholder Impact

• Shareholders: Minimal impact as these are routine, non-discretionary sales for tax purposes and do not signal a change in the executive's confidence or company fundamentals.
• Employees: No direct impact on employees.

Key Dates

Recommendation

The reported transactions are routine 'sell-to-cover' sales by an executive to satisfy tax obligations upon the vesting of restricted stock units. These non-discretionary sales do not reflect a change in the executive's investment conviction or the company's fundamentals, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Kura Oncology, KURA, Form 4, insider transaction, stock sale, restricted stock units, RSU vesting, tax obligations, executive compensation